Adalvo is a leading global B2B pharmaceutical company, combining a differentiated portfolio with an end-to-end platform that brings complex generics, 505(b)(2) products, peptides, biosimilars and GLP-1s to market quickly and sustains reliable supply over the long term. From portfolio selection through development, regulatory and supply to commercial out-licensing, Adalvo partners with over 170 pharmaceutical companies across more than 140 countries, turning technical capability into repeatable, first-to-market delivery. Headquartered in Malta and backed by EQT, Adalvo is committed to making a difference for patients around the world.
| Website | http://www.adalvo.com |
| Revenue | $13.9 million |
| Employees | 325 (262 on RocketReach) |
| Founded | 2020 |
| Phone | +356 2248 5944 |
| Technologies |
HTML
,
Twitter
,
Microsoft Outlook
+4 more
(view full list)
|
| Industry | Pharmaceutical Manufacturing |
| Keywords | Pharmaceutical, B2b, Commercial Partnerships, Global, Drug Development, Drug Manufacturing, Pharmaceutical Sales, Healthcare, Biopharma, Pharma, Life Sciences, Drug Distribution, Clinical Trials, Regulatory Affairs, Supply Chain, International Trade, Wholesale Distribution, Generic Drugs, Pharmaceutical Marketing |
| Competitors | Boehringer Ingelheim, Amgen, Teva Pharmaceuticals, Sandoz, SUN PHARMA, Cipla, Lupin Limited, Accord Healthcare Greece, Mylan Belgium, DNBIZ +40 more (view full list) |
Looking for a particular Adalvo employee's phone or email?
The Adalvo annual revenue was $13.9 million in 2026.
Frank Fischer is the CIO of Adalvo.
262 people are employed at Adalvo.